| Literature DB >> 20416509 |
Natalya A Smirnova1, Ilay Rakhman, Natalia Moroz, Manuela Basso, Jimmy Payappilly, Sergey Kazakov, Francisco Hernandez-Guzman, Irina N Gaisina, Alan P Kozikowski, Rajiv R Ratan, Irina G Gazaryan.
Abstract
Small molecules inhibiting hypoxia inducible factor (HIF) prolyl hydroxylases (PHDs) are the focus of drug development efforts directed toward the treatment of ischemia and metabolic imbalance. A cell-based reporter produced by fusing HIF-1 alpha oxygen degradable domain (ODD) to luciferase was shown to work as a capture assay monitoring stability of the overexpressed luciferase-labeled HIF PHD substrate under conditions more physiological than in vitro test tubes. High throughput screening identified novel catechol and oxyquinoline pharmacophores with a "branching motif" immediately adjacent to a Fe-binding motif that fits selectively into the HIF PHD active site in in silico models. In accord with their structure-activity relationship in the primary screen, the best "hits" stabilize HIF1 alpha, upregulate known HIF target genes in a human neuronal line, and exert neuroprotective effects in established model of oxidative stress in cortical neurons. (c) 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20416509 PMCID: PMC4327942 DOI: 10.1016/j.chembiol.2010.03.008
Source DB: PubMed Journal: Chem Biol ISSN: 1074-5521